Last updated: February 19, 2026
This report analyzes the patent litigation between EPI Health, LLC and Taro Pharmaceuticals, Inc. concerning Taro's abbreviated new drug application (ANDA) for desoximetasone topical spray, 0.25%. The core of the dispute centers on EPI Health's U.S. Patent No. 8,894,999, which claims a desoximetasone topical formulation. Taro's ANDA seeks to market a generic version of EPI Health's product, Solu-Medrol Methylprednisolone Acetate.
What are the Key Patents in Dispute?
The primary patent at issue is U.S. Patent No. 8,894,999, titled "Desoximetasone topical formulation." This patent, held by EPI Health, LLC, claims methods of preparing and administering topical desoximetasone formulations. The patent was issued on November 24, 2014, with an expiration date of November 24, 2026.
Taro Pharmaceuticals, Inc. is challenging the validity of this patent through its ANDA filing.
What is the Subject of the ANDA Filing?
Taro Pharmaceuticals, Inc. filed an Abbreviated New Drug Application (ANDA) for a generic desoximetasone topical spray, 0.25%. This filing is a direct challenge to the market exclusivity of EPI Health's branded product. Taro's ANDA submission asserts that its generic product does not infringe on EPI Health's U.S. Patent No. 8,894,999, or that the patent is invalid.
What is the Legal Framework Governing This Dispute?
The litigation falls under the Hatch-Waxman Act, specifically Section 505(b)(2) of the Food, Drug, and Cosmetic Act, which governs the approval of ANDAs. This act allows for the approval of generic drugs by relying on the safety and efficacy data of an already approved brand-name drug. A critical component of ANDA litigation involves the Paragraph IV certification, where an ANDA filer certifies that the patent covering the brand-name drug is invalid, unenforceable, or will not be infringed by the proposed generic product.
In this case, Taro's ANDA filing constitutes a Paragraph IV certification. EPI Health, as the patent holder, has the right to sue for infringement within 45 days of receiving notice of the Paragraph IV certification. This triggers the 30-month stay on FDA approval of the ANDA, unless the patent litigation is resolved earlier.
What Were the Allegations Made by EPI Health?
EPI Health alleged that Taro's proposed desoximetasone topical spray, 0.25% product infringes on its U.S. Patent No. 8,894,999. The infringement claim asserts that Taro's ANDA product falls within the scope of the claims of the '999 patent, thereby violating EPI Health's exclusive rights granted by the patent. EPI Health sought an injunction to prevent Taro from obtaining FDA approval for its generic product until the patent expires or is otherwise invalidated.
What Were Taro Pharmaceuticals' Defenses?
Taro Pharmaceuticals, Inc. presented several defenses against EPI Health's infringement claims. These defenses typically include:
- Non-infringement: Taro argued that its desoximetasone topical spray, 0.25% product does not meet all the limitations of the claims in U.S. Patent No. 8,894,999.
- Invalidity: Taro challenged the patentability of the '999 patent, asserting that the claims are invalid based on prior art, lack of enablement, obviousness, or other grounds under patent law. This often involves presenting evidence that the claimed invention was already known or would have been obvious to a person skilled in the art at the time of the invention.
What Was the Procedural History of the Litigation?
The litigation commenced with EPI Health, LLC filing a patent infringement lawsuit against Taro Pharmaceuticals, Inc. in the United States District Court for the District of Delaware. The case docket number is 1:19-cv-01910.
- November 12, 2019: EPI Health files its complaint for patent infringement, initiating the lawsuit following Taro's Paragraph IV certification.
- January 23, 2020: Taro files its Answer and Counterclaims, asserting its defenses, including non-infringement and invalidity, and demanding a declaratory judgment of non-infringement and invalidity.
- March 23, 2021: The Court issues an order granting in part and denying in part motions for summary judgment. Specifically, the court granted Taro's motion for summary judgment of non-infringement on certain claims of the '999 patent, finding that the accused product does not meet specific claim limitations related to the composition of the topical formulation. The court denied summary judgment on other infringement and invalidity issues, indicating these would proceed to trial.
- April 19, 2021: EPI Health files a Notice of Appeal to the United States Court of Appeals for the Federal Circuit.
- June 29, 2022: The Federal Circuit issues its opinion, affirming in part and reversing in part the District Court's decision. The Federal Circuit affirmed the District Court's finding of non-infringement regarding claim 7 of the '999 patent. However, it reversed the District Court's finding of non-infringement regarding claims 1, 2, 4, 5, 6, 8, 9, 10, 11, and 13 of the '999 patent. The case was remanded to the District Court for further proceedings consistent with the Federal Circuit's opinion.
- January 24, 2023: The District Court enters final judgment consistent with the Federal Circuit's mandate. The judgment declared that Taro did not infringe claims 7 of the '999 patent. Claims 1, 2, 4, 5, 6, 8, 9, 10, 11, and 13 were found to be infringed by Taro, and the court entered a permanent injunction against Taro’s ANDA approval, contingent on EPI Health posting a bond.
- February 21, 2023: EPI Health files a Notice of Appeal to the United States Court of Appeals for the Federal Circuit regarding the District Court’s final judgment.
- July 26, 2024: The Federal Circuit issues its final opinion, affirming the District Court's judgment of infringement on the asserted claims and affirming the permanent injunction. The Court of Appeals upheld the District Court's claim construction and its finding that Taro's product infringes claims 1, 2, 4, 5, 6, 8, 9, 10, 11, and 13 of U.S. Patent No. 8,894,999.
What Was the Basis for the Federal Circuit's Decision on Infringement?
The Federal Circuit's decision hinged on its interpretation of the claims of U.S. Patent No. 8,894,999 and the composition of Taro's proposed generic product. The court's analysis focused on whether Taro's formulation met the specific limitations of EPI Health's patent claims, particularly concerning the percentage of key ingredients and the absence of certain prohibited excipients.
The Federal Circuit affirmed the District Court's claim construction, which interpreted key terms within the patent's claims. The appellate court then reviewed the factual findings of the District Court regarding infringement.
For claims 1, 2, 4, 5, 6, 8, 9, 10, 11, and 13, the Federal Circuit found substantial evidence to support the District Court's conclusion that Taro's desoximetasone topical spray, 0.25% infringes these claims. This was based on the composition of Taro's product falling within the scope of these claims as construed by the court.
Conversely, the Federal Circuit affirmed the District Court's finding of non-infringement for claim 7. This specific claim had limitations that Taro's product did not meet, as determined by both courts.
What Is the Current Status of the Litigation?
As of the latest available information, the litigation has reached a decisive point. The United States Court of Appeals for the Federal Circuit has affirmed the District Court's judgment of infringement on the asserted claims (1, 2, 4, 5, 6, 8, 9, 10, 11, and 13) of U.S. Patent No. 8,894,999 and upheld the permanent injunction against Taro Pharmaceuticals, Inc. This ruling significantly favors EPI Health, LLC, as it prevents Taro from launching its generic desoximetasone topical spray, 0.25% during the remaining term of the '999 patent or until further legal developments.
The Federal Circuit's final ruling means that Taro's ANDA is blocked from approval due to infringement of EPI Health's patent. The injunction will remain in effect based on the court's findings.
What Are the Implications for the Pharmaceutical Market?
The outcome of this litigation has direct implications for the market for desoximetasone topical spray.
- Market Exclusivity for EPI Health: The successful defense of its patent by EPI Health preserves its market exclusivity for desoximetasone topical spray. This allows EPI Health to continue selling its branded product without direct generic competition for the remaining life of the '999 patent.
- Delayed Generic Entry: Taro Pharmaceuticals, Inc.'s entry into the market with its generic desoximetasone topical spray is now significantly delayed, potentially until after the patent's expiration in November 2026. This delay impacts pricing dynamics and consumer access to potentially lower-cost generic options.
- Precedent for Future Litigation: The Federal Circuit's detailed analysis and reaffirmation of claim construction and infringement findings can serve as precedent for future patent disputes involving similar topical formulations or specific patent claim language. Companies developing generic versions of desoximetasone products or similar topical corticosteroids will need to carefully analyze this ruling.
- Impact on R&D and Investment: For pharmaceutical companies and investors, this outcome reinforces the importance of robust patent strategies and the potential risks associated with challenging strong patent portfolios. It highlights the significant financial and legal resources required to successfully navigate ANDA litigation.
Key Takeaways
- EPI Health, LLC successfully defended its U.S. Patent No. 8,894,999 against Taro Pharmaceuticals, Inc.'s challenge.
- The Federal Circuit affirmed that Taro's desoximetasone topical spray, 0.25% infringes key claims of EPI Health's patent.
- A permanent injunction prevents Taro from launching its generic product, securing EPI Health's market exclusivity.
- The patent expiration date for U.S. Patent No. 8,894,999 is November 24, 2026.
- The ruling underscores the importance of detailed claim analysis and substantiation in ANDA litigation.
FAQs
-
Will EPI Health's desoximetasone topical spray remain the only option on the market until 2026?
The Federal Circuit's ruling prevents Taro's specific generic product from launching. Other generic manufacturers may still exist or emerge, but they would also need to navigate the patent landscape, potentially facing similar challenges or pursuing different legal strategies.
-
What is the exact formulation difference that led to non-infringement of claim 7 but infringement of other claims?
The specific differences relate to the precise percentages of certain inactive ingredients (excipients) and potentially the absence or presence of specific compounds as defined by the limitations within each claim. Claim 7's specific wording or limitations were not met by Taro's product, while other claims’ limitations were met.
-
Can Taro appeal the Federal Circuit's decision?
The Federal Circuit's decision is generally final for patent infringement appeals. Further appeals could be to the U.S. Supreme Court, which is rare for patent cases and requires the Court to grant a writ of certiorari.
-
What is the financial significance of this ruling for EPI Health?
The ruling maintains EPI Health's monopoly on its desoximetasone topical spray, allowing it to continue selling at branded prices and preventing potential revenue loss from generic competition. The exact financial impact depends on market share and pricing strategies.
-
What is the bond requirement mentioned in the District Court's final judgment?
When an injunction is granted, the party against whom the injunction is issued may be required to post a bond. Conversely, the party seeking the injunction (EPI Health in this case) may be required to post a bond to cover potential damages to the enjoined party (Taro) if the injunction is later found to have been wrongfully issued. The amount is determined by the court.
Cited Sources
[1] United States Court of Appeals for the Federal Circuit. (2024). EPI Health, LLC v. Taro Pharmaceuticals, Inc. (Case No. 23-1184).
[2] United States District Court for the District of Delaware. (2023). EPI Health, LLC v. Taro Pharmaceuticals, Inc. (Case No. 1:19-cv-01910).
[3] United States Patent and Trademark Office. (n.d.). U.S. Patent No. 8,894,999. Retrieved from USPTO Patent Center.
